MedTrace Logo

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

NCT01375127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2013-10-29

Study results available
· View outcomes & findings →

Summary

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Tofacitinib

Subjects who previously took 15 mg BID or 30 mg BID

DRUG

Tofacitinib

Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01375127 on ClinicalTrials.gov